Pfizer Inc.’s (PFE) 10-µg booster dose of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children received Emergency Use Authorization from the U.S. Food and Drug Administration on October 12, 2022. This approval is yet another feather in PFE’s cap. This development should boost its share price. PFE has co-developed the vaccine with BioNTech (BNTX).
Moreover, amid the current uncertain market conditions, PFE could cushion one’s portfolio with its reliable dividends. PFE paid dividends for 32 consecutive years. Its dividend payouts have grown at a 5.9% CAGR over the past five years and a 5.7% CAGR over the past three years. Its current dividend yield is 3.63%, while its four-year average yield is 3.62%.
